NovoCure Spikes On FDA Approval
Warrior Trading | Jul 14, 2016 10:02AM ET
Novocure Ltd. (NASDAQ:NVCR), a cancer therapy company yesterday announced that the FDA approved its second generation Optune system. The new Optune system is a lightner Tumor Treating Fields delivery system for glioblastoma (GBM) patients.h3 NovoCure Limited CEO and CFO Comments/h3
h3 NVCR Technical Analysis/h3We are happy to receive FDA approval of our second generation Optune system,” said Asaf Danziger, Novocure’s Chief Executive Officer. “We believe the improvements incorporated into the second generation Optune system will make a big difference to the patients and families who face this devastating disease every day. We will continue to work to improve our technology and patient experience.
“From the start, Novocure’s mission has been to improve the lives of cancer patients,” said Mike Ambrogi, Novocure’s Chief Operating Officer. “The second generation Optune system was designed to be more convenient and to make it even easier for patients to incorporate treatment with TTFields into their lives. We have received positive feedback from our second generation Optune patients in Europe, and we are excited to roll out our new device to patients in the United States. Business Wire
NVCR opened trading yesterday at $12.25 which was up from the previous days trading of $12.20. NVCR closed trading yesterday at $11.96 and spiked down after market to $12.65, equivalent to a 6% increase from the closing price. Taking a look at the daily chart we can see the last time NVCR traded above these levels was on June 10th when it traded at $13.41. Taking a closer look at the daily chart we can see that NVCR has been on an overall downward trend dating back to March 7th when it traded of $17.40. NVCR has a float of 35.76 million shares and traded below the normal daily trading volume on Wednesday. For trading purposes, I would like to see NVCR open trading on Thursday above $12.40 and if it does I would be looking to take a long position at the bell. My stop loss would be $0.20 from my entry position fearing anything more than that and the stock would start to fill in the gap up.
h3 Company Profile/h3NovoCure Limited, incorporated on February 11, 2000, is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death. A TTFields delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories. The electric fields are delivered through the non-invasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The therapy is designed to be delivered throughout the day and night. The Company has performed various pre-clinical research on TTFields and their effects in multiple solid tumor cancers. It is engaged in Phase II pilot and Phase III pivotal trials across multiple solid tumor types for TTFields. The Company has trained physicians at approximately 240 clinical centers in the United States; at over 60 clinical centers in Europe, including approximately 50 in Germany, and at over 60 clinical centers in Japan.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.